[go: up one dir, main page]

SG11201502599TA - Non-cross-linked acellular pertussis antigens for use in combination vaccines - Google Patents

Non-cross-linked acellular pertussis antigens for use in combination vaccines

Info

Publication number
SG11201502599TA
SG11201502599TA SG11201502599TA SG11201502599TA SG11201502599TA SG 11201502599T A SG11201502599T A SG 11201502599TA SG 11201502599T A SG11201502599T A SG 11201502599TA SG 11201502599T A SG11201502599T A SG 11201502599TA SG 11201502599T A SG11201502599T A SG 11201502599TA
Authority
SG
Singapore
Prior art keywords
cross
combination vaccines
acellular pertussis
pertussis antigens
linked acellular
Prior art date
Application number
SG11201502599TA
Inventor
Lorenzo Tarli
Mario Contorni
Alessandro Bartalesi
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of SG11201502599TA publication Critical patent/SG11201502599TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/30011—Nodaviridae
    • C12N2770/30034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
SG11201502599TA 2012-10-12 2013-10-11 Non-cross-linked acellular pertussis antigens for use in combination vaccines SG11201502599TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261713356P 2012-10-12 2012-10-12
PCT/EP2013/071372 WO2014057132A1 (en) 2012-10-12 2013-10-11 Non-cross-linked acellular pertussis antigens for use in combination vaccines

Publications (1)

Publication Number Publication Date
SG11201502599TA true SG11201502599TA (en) 2015-05-28

Family

ID=49326692

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201502599TA SG11201502599TA (en) 2012-10-12 2013-10-11 Non-cross-linked acellular pertussis antigens for use in combination vaccines

Country Status (13)

Country Link
US (2) US20150273036A1 (en)
EP (2) EP3620172A1 (en)
JP (1) JP6440619B2 (en)
KR (1) KR20150065878A (en)
CN (1) CN104918634A (en)
AU (1) AU2013328548A1 (en)
BR (1) BR112015008040A2 (en)
CA (1) CA2886938A1 (en)
IL (1) IL238023A0 (en)
MX (3) MX2015004652A (en)
RU (1) RU2015111987A (en)
SG (1) SG11201502599TA (en)
WO (1) WO2014057132A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
AU2016248452B2 (en) * 2015-04-16 2018-05-31 Inventprise, Inc. Bordetella pertussis immunogenic vaccine compositions
US10881723B2 (en) * 2016-01-15 2021-01-05 Km Biologics Co., Ltd. Vaccine containing immobilized virus particles
KR102362777B1 (en) * 2018-03-27 2022-02-15 주식회사 녹십자 Method for obtaining bordetella pertussis related proteins comprising affinity chromatography
MY208608A (en) * 2021-04-20 2025-05-20 Km Biologics Co Ltd Liquid sextuple vaccine composition

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
DE3485094D1 (en) 1983-01-25 1991-10-31 Ciba Geigy Ag NEW PEPTIDE DERIVATIVES.
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4624918A (en) 1984-07-09 1986-11-25 Genentech, Inc. Purification process for hepatitis surface antigen and product thereof
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (en) 1985-07-05 1987-12-23 Sclavo Spa GLYCOPROTEIC CONJUGATES WITH TRIVALENT IMMUNOGENIC ACTIVITY
IT1223334B (en) * 1987-11-02 1990-09-19 Sclavo Spa IMMUNOLOGICALLY ACTIVE POLYPEPTIDES WITH AN ALTERED TOXICITY USEFUL FOR THE PREPARATION OF AN ANTIPERTOX VACCINE
GB8727489D0 (en) * 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
NL8802046A (en) 1988-08-18 1990-03-16 Gen Electric POLYMER MIXTURE WITH POLYESTER AND ALKANE SULFONATE, OBJECTS THEREFORE.
DE3841091A1 (en) 1988-12-07 1990-06-13 Behringwerke Ag SYNTHETIC ANTIGENS, METHOD FOR THEIR PRODUCTION AND THEIR USE
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
DE69022106T2 (en) 1989-04-28 1996-02-15 Sclavo Spa Pertussis toxin mutants, the same producing Bordetella strains and their use as a vaccine against pertussis.
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
EP0482068A1 (en) 1989-07-14 1992-04-29 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
IT1237764B (en) 1989-11-10 1993-06-17 Eniricerche Spa SYNTHETIC PEPTIDES USEFUL AS UNIVERSAL CARRIERS FOR THE PREPARATION OF IMMUNOGENIC CONJUGATES AND THEIR USE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES.
SE466259B (en) 1990-05-31 1992-01-20 Arne Forsgren PROTEIN D - AN IGD BINDING PROTEIN FROM HAEMOPHILUS INFLUENZAE, AND THE USE OF THIS FOR ANALYSIS, VACCINES AND PURPOSE
DE69113564T2 (en) 1990-08-13 1996-05-30 American Cyanamid Co Bordetella pertussis fiber hemagglutinin as a carrier for conjugated vaccine.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
IT1262896B (en) 1992-03-06 1996-07-22 CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN (HSP) AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES.
RU2160120C2 (en) 1992-05-23 2000-12-10 Смитклайн Бичам Байолоджикалс С.А. Combined vaccine based on surface hepatitis b virus antigen, method of preparation thereof, and method for preventing hepatitis b infection in man
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
GB9216351D0 (en) 1992-07-31 1992-09-16 Wellcome Found Vaccine production
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
JP3828145B2 (en) 1993-09-22 2006-10-04 ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン A method for the activation of soluble carbohydrates using a novel cyanating reagent for the production of immunogenic components
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
ATE205724T1 (en) 1995-06-07 2001-10-15 Smithkline Beecham Biolog VACCINE WITH A POLYSACCHARIDE ANTIGEN CARRIER PROTEIN CONJUGATE AND FREE CARRIER PROTEIN
CZ288908B6 (en) 1995-06-23 2001-09-12 Smithkline Beecham Biologicals S. A. Compound vaccine, this vaccine in the form of a kit, process of its preparation and use
SI9720050B (en) * 1996-07-02 2001-12-31 Connaught Lab Multivalent dtp-polio vaccines
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
BR9714980A (en) * 1997-09-15 2001-11-06 Pasteur Merieux Msd Multivalent vaccines
DK1075276T3 (en) 1998-05-07 2008-02-11 Corixa Corp Adjuvant composition and methods for its use
WO2000010599A2 (en) 1998-08-19 2000-03-02 North American Vaccine, Inc. IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
DE122009000054I1 (en) 1999-03-19 2009-12-31 Glaxosmithkline Biolog Sa VACCINE AGAINST BACTERIAL ANTIGENE
EP1165796A2 (en) 1999-04-09 2002-01-02 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
DZ3399A1 (en) 2000-06-29 2002-01-03 Smithkline Beecham Biolog VERSATILE VACCINE COMPOSITION
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
GB0202901D0 (en) 2002-02-07 2002-03-27 Glaxosmithkline Biolog Sa Novel vaccine
ES2504166T3 (en) 2002-09-13 2014-10-08 Novartis Vaccines And Diagnostics, Inc. Group B strep vaccine
DK1742659T3 (en) 2004-04-05 2013-06-03 Zoetis P Llc Microfluidized oil-in-water emulsions and vaccine compositions
NZ550533A (en) * 2004-04-30 2010-02-26 Novartis Vaccines & Diagnostic Meningococcal conjugate vaccination comprising N. meningitidis and diphtheria toxin
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
TWI382019B (en) 2005-08-19 2013-01-11 Array Biopharma Inc Aminodiazepines as toll-like receptor modulators
AR056591A1 (en) 2005-10-28 2007-10-10 Vaxinnate Corp LIGHT POLYPEPTIDES FOR RECEIVER 4 SIMIL TOLL (TLR4)
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
BRPI0620418A2 (en) * 2005-12-23 2011-11-08 Glaxosmithkline Biolog Sa method for immunizing a human patient against a disease, uses at least two and at least seven, ten, eleven, thirteen or fourteen conjugates and vaccines, and
FR2896162B1 (en) 2006-01-13 2008-02-15 Sanofi Pasteur Sa EMULSION OIL IN THERMOREVERSIBLE WATER
JP5356228B2 (en) 2006-07-07 2013-12-04 ギリアード サイエンシーズ， インコーポレイテッド Regulator of toll-like receptor 7
US8956625B2 (en) 2006-09-07 2015-02-17 Glaxosmithkline Biologicals, S.A. Inactivated polio vaccines
WO2008043774A1 (en) 2006-10-12 2008-04-17 Glaxosmithkline Biologicals S.A. Vaccine comprising an oil in water emulsion adjuvant
GB0622282D0 (en) 2006-11-08 2006-12-20 Novartis Ag Quality control methods
CA2685506A1 (en) * 2007-05-02 2008-11-13 Glaxosmithkline Biologicals S.A. Vaccine
PE20091236A1 (en) 2007-11-22 2009-09-16 Astrazeneca Ab PYRIMIDINE DERIVATIVES AS IMMUNOMODULATORS OF TLR7
US8092813B1 (en) 2007-12-28 2012-01-10 Novartis Ag Polychlorinated biphenyls and squalene-containing adjuvants
HRP20150892T1 (en) 2008-03-03 2015-09-25 Novartis Ag COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR ACTIVITY
CN101980707B (en) 2008-03-24 2015-05-20 4Sc股份有限公司 New substituted imidazoquinoline compounds
EP2313111B1 (en) 2008-08-01 2013-09-04 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
CA2735404C (en) 2008-08-28 2013-04-16 Novartis Ag Production of squalene from hyper-producing yeasts
WO2010144734A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
PT2343052E (en) 2009-12-03 2013-08-28 Novartis Ag Hydrophilic filtration during manufacture of vaccine adjuvants
NZ600254A (en) 2009-12-03 2013-10-25 Novartis Ag Arranging interaction and back pressure chambers for microfluidization
DK2356983T3 (en) 2009-12-03 2013-03-11 Novartis Ag Circulation of constituents during homogenization of emulsions
PT3103784T (en) 2010-05-12 2019-05-20 Novartis Ag Manufacture of an oil-in-water emulsion comprising squalene
GB201009673D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
GB201009671D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
GB201009676D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
CN103313725B (en) 2010-09-01 2016-06-29 诺华有限公司 Immunopotentiator Adsorbs Insoluble Metal Ions

Also Published As

Publication number Publication date
MX2019002024A (en) 2019-07-22
MX2019013641A (en) 2020-01-21
US20200138927A1 (en) 2020-05-07
BR112015008040A2 (en) 2017-07-04
EP2906239A1 (en) 2015-08-19
US20150273036A1 (en) 2015-10-01
MX2015004652A (en) 2015-08-05
JP6440619B2 (en) 2018-12-19
IL238023A0 (en) 2015-05-31
RU2015111987A (en) 2016-12-10
AU2013328548A1 (en) 2015-05-07
KR20150065878A (en) 2015-06-15
WO2014057132A1 (en) 2014-04-17
CN104918634A (en) 2015-09-16
EP3620172A1 (en) 2020-03-11
JP2015533148A (en) 2015-11-19
CA2886938A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
ZA201500784B (en) Mycobacterial antigen vaccine
ZA201308461B (en) Multiple antigen presenting immunogenic composition and methods and uses thereof
PL2647387T3 (en) Vaccine Composition
ZA201404712B (en) Composite antigenic sequences and vaccines
IL241271A (en) Acellular pertussis vaccine
IL234604A (en) Carbohydrate-glycolipid conjugate vaccines
IL234695B (en) Antigenic compositions and methods
IL242584B (en) Immunogenic composition for use in therapy
SG11201502219XA (en) Back grinding sheet
IL238023A0 (en) Non-cross-linked acellular pertussis antigens for use in combination vaccines
EP2872530A4 (en) Kif20a epitope peptides for th1 cells and vaccines containing the same
ZA201402553B (en) Vaccines for human papilloma virus and methods for using the same
ZA201306245B (en) Combination vaccines
PL2591798T3 (en) Vaccine for use in tumor immunotherapy
SG11201505086QA (en) Immunogenic composition comprising mycoplasma antigens
EP2872531A4 (en) Ly6k epitope peptides for th1 cells and vaccines containing the same
EP2929894A4 (en) Vaccination adjuvant, and preparation and vaccines containing same
ZA201405107B (en) Mtb-c vaccine against asthma
ZA201407309B (en) Antigens and antigen combinations
ZA201504231B (en) Leptospira with increased antigenic mass
ZA201506581B (en) Acellular pertussis vaccine
ZA201508585B (en) Immunogenic composition for use in therapy
IL228649B (en) Immunogenic compositions for use in therapy
ZA201307648B (en) Antigenic formulation
GB201108982D0 (en) Vaccines